Eli Lilly showcases emerging pipeline to investors
Eli Lilly and Co (NYSE: LLY) has showcased its emerging pipeline to potential investors, highlighting its potential to launch 20 new products in the 10 years beginning in 2014 through to 2023.
Additionally, Lilly believes it could launch an average of two new indications or line extensions for already-approved products each year during this time. Their efforts are primarily focused in five key areas, which are diabetes, oncology, immunology, neurodegeneration and pain. While the other four are established core markets for Lilly, pain is one emerging area that their research is targeting.
In oncology, their portfolio contains a range of assets including Cyramza (ramucirumab), Portrazza (necitumumab), olaratumab and abemaciclib. Olaratumab was granted priority review by the FDA at the beginning of May for the treatment advanced soft tissue sarcoma. The immune-oncology portfolio will have five differentiated molecules in clinical testing by the end of this year, with the potential to have as many as 11 by the end of 2018.
The immunology field is Lilly’s newest therapeutic area. Taltz (ixekizumab) received FDA and EMA approval for the treatment of plaque psoriasis, while the company awaits the results from their new drug application for rheumatoid arthritis drug, baricitinib.
Lilly’s focus on Alzheimer’s is underlined by their research portfolio with seven molecules in human testing. The company recently announced the continuation of a Phase III trial, in collaboration with AstraZeneca for AZD3293, which attempts to prevent the formation of amyloid plaque and ultimately slow Alzheimer’s disease.
In terms of pain, Lilly is focussed on non-opioid treatments for chronic pain. The company has two late stage trial drugs, galcanezumab and tanezumab, for the treatment of various pain-related issues.
Jan Lundberg, executive VP of science and technology and president at Lilly Research Laboratories, says: “We have improved the productivity and success of our pipeline through discrete actions aimed at enhancing focus, quality and speed, and by positioning ourselves as an attractive partner for external innovation opportunities. These improvements have led to the potential for unprecedented R&D output.”
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Zepbound …
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Omvoh …